Marwan Sabbagh, MD, FAAN, CCRI, prepared useful Practice Aids pertaining to Alzheimer's disease for this CME activity titled, "Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease: What Are the Implications for Treatment?" For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2FBgpZ0. CME credit will be available until January 29, 2020.
Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease: What Are the Implications for Treatment?
1. This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
Quick Links to Tools for Assessing
Cognitive Function in Clinical Practice
PRACTICE AID
Mini Mental State Examination (MMSE)
https://www.uml.edu/docs/Mini%20Mental%20State%20Exam_tcm18-169319.pdf
Montreal Cognitive Assessment (MoCA)
http://dhhs.ne.gov/children_family_services/ProtectionSafetyPolicy/
APS%20Policy/MoCA-Test-English%207.1.pdf
Access the activity, “Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease:
What Are the Implications for Treatment?” at www.peerview.com/JJS40.
2. This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
Assessing the Role of Biomarkers
in the Early Detection of Alzheimer’s
Disease1,2
Aβ: amyloid beta; Aβ42
: amyloid beta 42; CSF: cerebrospinal fluid; FDG-PET: fluorodeoxyglucose-positron emission tomography; MCI: mild cognitive impairment; MRI: magnetic resonance imaging.
1. Albert MS et al. Alzheimers Dement. 2011;7:270-279.
2. Jack CR Jr et al. Lancet Neurol. 2010;9:119-128.
PRACTICE AID
Access the activity, “Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease:
What Are the Implications for Treatment?” at www.peerview.com/JJS40.
BiomarkerAbnormality
Max
Min
Time
MCI
Dementia
Detection
threshold
CSF Aβ42
Amyloid PET
CSF tau
MRI + FDG-PET
Cognitive impairment
High
risk
Lowrisk
Normal
Testing and Biomarkers
CSF
• Aβ42
• Total tau
• P-tau
Amyloid PET
• Aβ deposition
FDG-PET
• Reduced glucose metabolism or
perfusion of temporoparietal cortex
Volumetric MRI
• Hippocampal volume loss
• Brain atrophy rate